Research Presentation Session

RPS 209 - Liver oncology

Lectures

1
RPS 209 - Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

RPS 209 - Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

04:40B. Rocco, Rome / IT

2
RPS 209 - Feasibility of intra-arterial Lu-177 DOTA TATE peptide receptor radionucleotide therapy in metastatic neuroendocrine tumours with liver dominant disease

RPS 209 - Feasibility of intra-arterial Lu-177 DOTA TATE peptide receptor radionucleotide therapy in metastatic neuroendocrine tumours with liver dominant disease

04:59M. Palaniswamy, Chennai / India

3
RPS 209 - Transarterial chemoembolisation in patients with hepatocellular carcinoma: impact of low-dose doxorubicin on post-embolisation syndrome and overall survival

RPS 209 - Transarterial chemoembolisation in patients with hepatocellular carcinoma: impact of low-dose doxorubicin on post-embolisation syndrome and overall survival

04:55A. Bessar, Zagazig / Egypt

4
RPS 209 - Circulating tumour cells in hepatocellular carcinoma under interventional radiological treatment: cTACE vs MWA

RPS 209 - Circulating tumour cells in hepatocellular carcinoma under interventional radiological treatment: cTACE vs MWA

04:05T. Vogl, Frankfurt / Germany

5
RPS 209 - Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a retrospective study

RPS 209 - Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a retrospective study

06:36L. Zheng, Lishui / China

PEP Subscription Required

This course is only accessible for ESR Premium Education Package subscribers.